Avellino Labs is a genetic services provider specializing in data, diagnostics, and gene therapies for eye care. It developed the first genetic test for corneal dystrophy in 2008 and was named a World Economic Forum Technology Pioneer in 2015. In 2016 it partnered with Ulster University to develop gene editing technologies. Avellino aims to pioneer precision medicine for eye care by identifying patients for treatment and lifestyle management using genetic diagnostics until gene therapies are approved. It is developing the first gene therapies for corneal dystrophies using an innovative "dual-cutting" CRISPR/Cas9 method to solve previous issues. Avellino seeks to expand precision medicine through advanced genetic analysis, more diagnostic tests, and novel gene therapies

1. Avellino Labs
THE FUTURE OF GENE THERAPY AND MOLECULAR DIAGNOSTICS
Eric Bernabei
Chief Sales and Marketing Officer

2. Avellino Labs
8
Genetic services provider specializing in data, diagnostics, and therapies.
2008 1st genetic test to detect corneal dystrophy
2015 Named Technology Pioneer - World Economic Forum
2016
Partnered with Ulster University to develop
state-of-the-art gene editing
200
8
2015
2016

3. 10
Board of Directors
Thomas Kim, Esq
Board Member
Chief Strategy Officer and
Corporate Secretary,
Avellino Labs
Sang Yup Lee, PhD
Board Member
Distinguished Professor,
Korea Advanced Institute of Science
and
Technology (KAIST)
John Marshall, PhD, MBE
Board Member
Director of Scientific and
Medical Affairs
James V. Mazzo
Board Member
Global President for Carl Zeiss Meditec,
Governing Board Position of American
Society of Cataract and Refractive
Surgery (ASCRS) Public Trustee
Gene Lee
Founder &
Chairman of the
Board,
Avellino Labs

4. 11
Proven Executive Management Team & Clinical Advisors
Gene Lee
Chairman & President
Eric Bernabei
Chief Sales & Marketing
Officer
Tara McMullen
Chief R&D Officer
John Marshall, PhD, MBE
Board Member
Director of Scientific and
Medical Affairs
James V. Mazzo
Board Member
Global President for Carl Zeiss Meditec,
Governing Board Position of American
Society of Cataract and Refractive
Surgery (ASCRS) Public Trustee
Terry Kim, MDAnthony Aldave, MD Burkhard Dick, MD
Dick Lindstrom, MD
Edward Holland, MD
Eric Donnenfeld, MD
Andrea Cusumano, MD
EK Kim, MD, PhD
David Hwang, MD Shigeru Kinoshita, MD
Elizabeth Yeu, MD

5. Avellino Labs
GENETIC DATA
MOLECULAR
DIAGNOSTICS
GENE THERAPY
DEVELOPMENT
Pioneering Precision Medicine for Eye Care

6. 21
Avellino’s Unique Advantage - Partner Diagnostics and Therapeutics
Identifying patients for treatment & lifestyle management until gene therapies are approved
2008 2019
1
Test for
1 TGFBI mutation
(GCD2)
2
GCD1,GCD2
2014
5
GCD1, GCD2, LCD1,
TBCD,RBCD
2015 2017
201
70 CD
Mutations
+
75 Gene NGS Panel
for Keratoconus
Risk Factors
11
LCD I/IIIA, 2 vt LCD,
variant TBCD, GCD,
RBCD
Stephen Curry attributes shooting slump
to keratoconus

7. First Gene Therapies for Corneal Dystrophies
Desirable Location Characteristics
Model for all autosomal dominant genetic diseases
Status & treatment success easily observable
Small surface treatment area
Cornea turns over rapidly
Cornea easily accessible
22
Relatively large prevalence for rare eye disease
Desirable Treatment Metrics
Lattice Type 1 GCD 2 Reis-Bucklers Thiel-Behnke
Granular
R124C R124H R124L R555Q R555W

8. Avellino’s Novel Gene Therapy Technology Solves Cas9 Problem
21
“Dual-Cutting Method – ASNIP”
Avellino Lab’s ASNIPConventional CRISPR / Cas9
PAM
PAM
TGFBI gene
with mutation
TGFBI gene
with no mutation

9. Avellino - Expanding Precision Medicine
Advanced genetic data analysis algorithms.
Expanding diagnostic tests that can be easily
incorporated into any practice.
Innovative gene therapies and delivery
methods.
Physicians and patients are demanding personalized treatment for rare
diseases and Avellino will deliver:
2

10. Avellino Labs
THANK YOU